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B-cell chronic lymphocytic leukemia (B-
CLL) migration involves several mol-
ecules, including matrix metalloprotein-
ase–9 (MMP-9) and vascular endothelial
growth factor (VEGF). We have studied
whether VEGF regulates MMP-9. VEGF
significantly reduced MMP-9 protein ex-
pression in a dose-dependent manner,
measured by gelatin zymography. Block-
ing the VEGFR2 receptor restored MMP-9
levels, implicating this receptor in the
observed effect. Down-regulation of
MMP-9 by VEGF resulted in significant
inhibition of B-CLL cell migration through
Matrigel or human umbilical vein endothe-
lial cells, confirming the crucial role of
MMP-9 in these processes. Reverse-
transcription polymerase chain reaction
analyses revealed that VEGF regulated
MMP-9 at the transcriptional level. In-
deed, VEGF induced STAT1 tyrosine phos-
phorylation, and this was blocked by in-
hibiting VEGFR2. STAT1 was responsible
for MMP-9 down-regulation, as STAT1
gene silencing restored MMP-9 produc-
tion and B-CLL cell migration in the pres-
ence of VEGF. Thus, the levels of VEGF
and MMP-9 influence B-CLL cell expan-
sion and both molecules could constitute
therapeutic targets for this disease.
(Blood. 2010;115:846-849)
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) extravasation and
tissue infiltration involve several molecules, including vascular
endothelial growth factor (VEGF) and matrix metalloproteinase–9
(MMP-9).1-6 B-CLL cells produce both molecules,7,8 and we have
previously shown that, although constitutive MMP-9 expression is
required for cell migration, increasing this expression by binding of
exogenously added MMP-9 induces cell arrest.9 This suggests that
MMP-9 levels play an important role in B-CLL cell expansion and
localization in tissues. Understanding MMP-9 regulation is there-
fore crucial to define strategies that prevent B-CLL cell progres-
sion. Interestingly, anti-VEGF antibodies decreased MMP-9 expres-
sion,8 suggesting a link between both proteins. As several
physiologic stimuli increase VEGF (both autocrine and paracrine)
in the B-CLL cell microenvironment,1,2 we have studied the
functional effects of elevated VEGF levels on MMP-9 expression
and B-CLL cell migration.
Methods
Approval was obtained from the review boards of the Hospital Clínico
Universitario, Valencia, Spain and the Hospital Universitario Puerta de
Hierro, Madrid, Spain for these studies. Informed consent was obtained in
accordance with the Declaration of Helsinki.
Patients and cells
CD5 B lymphocytes were purified from peripheral blood samples from
15 B-CLL patients (supplemental Table 1, available on the Blood website;
see the Supplemental Materials link at the top of the online article) using
Ficoll-Hypaque (Nycomed) centrifugation and negative selection with
anti–CD3-conjugated Dynabeads (Dynal Biotech ASA). The resulting
B-cell population, determined by flow cytometry, was more than 95%
CD19 and more than 90% CD5. Human umbilical vein endothelial cells
(HUVECs) were provided by Dr M. L. Botella and cultured as described.5
Additional materials and methods are available as supplemental data.
Results and discussion
To determine whether MMP-9 was regulated by VEGF, B-CLL
cells were incubated with or without 20 or 200 ng/mL VEGF for
24 hours and the conditioned media analyzed by gelatin zymogra-
phy. As shown in Figure 1A for 4 representative samples and
quantitated for 7, VEGF induced a significant, dose-dependent
down-regulation of secreted MMP-9. At 200 ng/mL (or 150 ng/mL,
not shown), MMP-9 average levels were reduced by 2.2-fold
compared with untreated cells.
Because the VEGF isoform used in our study (VEGF165) binds
VEGFR1 and VEGFR2,10,11 we aimed to identify the receptor
involved in the observed effect. B-CLL cells were incubated with
placenta growth factor-1 (PlGF), which selectively interacts with
VEGFR1 but not VEGFR2.12,13 Figure 1B shows that these cells
produced equal amounts of MMP-9 as untreated cells, thus
excluding VEGFR1 from the down-modulatory effect. Accord-
ingly, a specific VEGFR2 inhibitor14 restored the production of
MMP-9 by VEGF-treated cells (Figure 1B).
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We previously reported that MMP-9 is involved in B-CLL cell
migration elicited by the CXCL12 or CCL21 chemokines.5,6 We
therefore studied whether VEGF modulation of MMP-9 affected
this migration. Figure 1C and D shows that B-CLL cells migrated
through Matrigel or HUVECs (average 35.3% and 34.5%, respec-
tively,  90% CD19) in response to CXCL12. VEGF signifi-
cantly reduced this migration to the basal levels obtained in the
absence of chemokine. In agreement with the results shown in
Figure 1B, PlGF did not significantly affect cell migration, again
implicating VGFR2 and not VEGFR1 in the effect. Indeed, adding
the VEGFR2 inhibitor in combination with VEGF restored 70% of
cell migration in both systems, compared with untreated cells
(Figure 1C-D). Altogether, these results established that VEGFR2
is responsible for the decreased MMP-9 production in response to
VEGF and the subsequent impairment of B-CLL cell migration.
Reverse-transcription polymerase chain reaction studies re-
vealed that MMP-9 down-regulation was at the transcriptional
level, as VEGF also significantly reduced MMP-9 mRNA after 1 to
3 hours of exposure (Figure 2A). VEGFR2 has been shown to bind
and induce tyrosine phosphorylation of signal transducer and
activator of transcription (STAT) factors 1 and 6, in bovine aortic
endothelial cells.15 In B-CLL cells, the constitutive p-Ser727-
STAT1 and p-Ser727-STAT3 interact with VEGFR2 (and VEGFR1),
resulting in increased cell survival.16 STAT1 plays a critical role in
MMP-9 gene transcriptional suppression in response to interferons
in several cell systems.17-19 Interferons were also shown to down-
regulate MMP-9 production by B-CLL cells, although the mecha-
nism was not elucidated.8 We studied whether STAT1 was activated
by VEGF in B-CLL cells and involved in the subsequent MMP-9
gene and protein suppression. VEGF induced STAT1 tyrosine
phosphorylation, detected after 5 minutes of VEGF exposure (not
shown) and with maximal levels after 30 minutes (Figure 2B), then
decreasing after 60 minutes (not shown). In agreement with the
results shown in Figure 1, this effect was completely inhibited by
blocking VEGFR2 and was not induced by PlGF (Figure 2B). By
performing cellular fractionation analyses, we further demon-
strated that p-Y-STAT1 translocated to the nucleus in response to
VEGF (Figure 2C). A previous study did not find p-Ser727-STAT1
in the nucleus after VEGF stimulation,16 suggesting that Ser727
phosphorylation (which amplifies STAT1 transcriptional activity)
may not be necessary for VEGF-induced MMP-9 gene regulation.
To determine whether STAT1 activation was critical for MMP-9
regulation by VEGF, we transfected B-CLL cells with STAT1 siRNA
and measured the levels of MMP-9 upon VEGF treatment. VEGF did
not affect total STAT1 levels of untransfected cells (Figure 2D). STAT1
siRNA transfection reduced STAT1 expression by 40% (average of 3
patients; Figure 2D), and this was sufficient to restore production of
MMP-9 (Figure 2E). This effect was not the result of the transfection
procedure, as control siRNA-transfected cells had decreased MMP-9
expression on VEGF treatment (Figure 2E). STAT1 gene silencing also
restored migration of VEGF-treated B-CLL cells, whereas migration
remained inhibited on control siRNA-transfected cells (Figure 2F).
These results therefore show, for the first time, that the VEGF/
VEGFR2 axis induces STAT1 tyrosine phosphorylation and that
Figure 1. VEGF down-regulates MMP-9 and inhibits B-CLL cell
migration. (A) A total of 3  106 B-CLL cells were incubated in RPMI/0.1%
fetal bovine serum with the indicated concentrations of VEGF. After
24 hours, the conditioned media was concentrated and analyzed by
gelatin zymography. MMP-9 levels on untreated cells were normalized to
1, and average values (n  7) are shown. (B) B-CLL cells (n  8) were
untreated or treated with 200 ng/mL VEGF or PlGF, and in the presence or
absence of 5M VEGFR2 inhibitor I (R2 inhib.). After 24 hours, MMP-9
was analyzed and quantitated as explained. (C-D) A total of 5  105 B-CLL
cells (n  3) were untreated or treated with VEGF or PlGF for 30 minutes
and added to Transwell filters (5 m pore size) coated with Matrigel (A) or
activated HUVECs (B) in the presence of the cytokines. Some cells were
also pretreated with 5M VEGFR2 inhibitor I as indicated. CXCL12
(150 ng/mL) was added to the medium in the bottom chamber, except for
the control. After 24 hours, migrated cells were counted by flow cytometry.
Expression of CD19 on transmigrated cells ( 90%) was also analyzed by
flow cytometry. Values are the percentage of total cells added. Bars
represent SD. *P .05, **P .01, calculated by the 2-tailed Student t test.
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this is critical for the VEGF effect on MMP-9 expression and
cell migration.
Previous studies suggest that VEGF may have an important
pathogenic role in B-CLL. Increased bone marrow angiogenesis20
and VEGF urine and serum levels have been found in B-CLL
patients.7,20,21 Autocrine VEGF contributes to B-CLL cell motility3
as well as survival, as it mediates the antiapoptotic effect of
CD15422 and up-regulates several antiapoptotic genes.16 We now
report a novel role for VEGF in B-CLL, which affects malignant
cell migration/arrest and thus disease expansion. The ability to
block MMP-9 expression and cell migration was not observed in
the absence of exogenously added VEGF, indicating that it requires
higher VEGF levels than those constitutively produced by B-CLL
cells. Several physiologic stimuli can increase endogenous (hyp-
oxia,7 CD15422) or exogenous (stromal cells10,11) VEGF, and these
may be particularly important in B-CLL cell niches. Elevated
VEGF levels at these sites will therefore contribute to malignant
cell accumulation and progression of the disease. The differential
effect of low and high VEGF concentrations (perhaps resulting
from different VEGFR2 responses) resembles the distinct behavior
of high and low MMP-9 levels on B-CLL cell migration that we
previously reported,9 and both molecules, VEGF and MMP-9, may
constitute therapeutic targets for B-CLL.
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Figure 2. STAT1 plays a critical role in VEGF-induced
down-regulation of MMP-9. (A) A total of 107 B-CLL
cells were untreated or treated with 200 ng/mL VEGF for
the indicated times and mRNA expression analyzed by
reverse-transcribed polymerase chain reaction. Quantita-
tive values represent the average of 3 samples after
normalizing untreated cells values to 1. (B) A total of
3  106 B-CLL cells were lysed before (constitutive
[Const.]) or after 30 minutes of treatment with medium
(untreated [Unt.]) or the indicated stimuli. STAT1 tyrosine
701 phosphorylation (p-Y-STAT1) and total STAT1 (t-STAT1)
were analyzed by Western blotting, and normalized
average values (n  3) are shown. VR2 inhib. indicates
VEGF  VEGFR2 inhibitor I. (C) A total of 20  106
B-CLL cells treated with or without VEGF for 30 minutes
were lysed, and the nuclear and cytosolic fractions
separated and analyzed by Western blotting. The H4
histone was used as an internal nuclear marker. p-Y-
STAT1 indicates tyrosine 701 phosphorylated STAT1.
(D) B-CLL cells were untransfected (None) or transfected
with STAT1 siRNA or control siRNA, lysed, and analyzed
by Western blotting to determine STAT1 gene silencing
efficiency. Actin was used as an internal loading control.
Numbers represent the average t-STAT1/actin ratio after
normalizing untransfected values to 1. *P  .05 com-
pared with untransfected, untreated control. (E) B-CLL
cells untransfected or transfected with STAT1 or control
siRNA were treated with medium or 200 ng/mL VEGF for
24 hours. The conditioned media was concentrated and
MMP-9 levels analyzed by gelatin zymography. Normal-
ized average values (n  3) are shown. (F) B-CLL cells
untransfected or transfected with STAT1 or control siRNA
were treated with medium or VEGF and added to Trans-
well filters (5 m pore size) coated with Matrigel. Cell
migration was determined after 24 hours by flow cytom-
etry. Values are the percentage of total cells added.
*P  .05. **P  .01.
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